United States Acute Bacterial Skin and Skin Structure Infection Market Insight
Published: 23 May 2026 | Report Format: Electronic (PDF)
The market for ABSSSI in the US seems to be moving in a slight upward direction, sort of, with a CAGR of 6.9%, and that rise is mostly due to the growing frequency of bacterial skin infections. At the same time, there is also a counter-pressure, because more and more patients are getting admitted for complicated wound infections, which is affecting the market in an adverse way.
U.S. Acute Bacterial Skin and Skin Structure Infection Market Insights Forecasts to 2035
- The US Acute Bacterial Skin and Skin Structure Infection Market Size Was Estimated at USD 3.86 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.9% from 2025 to 2035
- The US Acute Bacterial Skin and Skin Structure Infection Market Size is Expected to Reach USD 7.51 Billion by 2035
Notable Insights for U.S. Acute Bacterial Skin and Skin Structure Infection Market
- By drug class, the lipoglycopeptide antibiotics segment dominated the market, generating approximately USD 1.54 Billion in revenue in 2024.
- Depending on the application, the market for hospital treatment is anticipated to experience the highest growth rate, due to growing prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) infection and demand for intravenous antibiotics.
- Like, nearly 67% of infectious disease treatment centers and hospitals in the U.S. use advanced broad-spectrum antibiotics along with combination therapies for acute bacterial skin and skin structure infection care, but closer to 59% of healthcare providers lean on rapid diagnostic testing as well as antimicrobial stewardship programs to boost treatment efficiency, and to help lower the risk of antibiotic resistance.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Healthcare-Focused Market Intelligence and Clinical Trend Evaluation
Decisions Advisors provides specialized healthcare research, disease burden analysis, treatment trend assessment, and strategic forecasting solutions to support informed business and clinical decisions across the life sciences industry.
- Evidence-Based Research Methodologies and Predictive Analytics
Our research approach integrates physician interviews, validated healthcare databases, epidemiological studies, and predictive analytical modelling to deliver accurate market forecasts and reliable therapeutic industry insights.
- Detailed Therapeutic Landscape and Innovation Assessment
We deliver comprehensive analysis of treatment advancements, regulatory developments, patient care trends, competitive positioning, and investment opportunities shaping healthcare and pharmaceutical markets globally.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US acute bacterial skin and skin structure infection market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Acute Bacterial Skin and Skin Structure Infection Market
- Pfizer Inc.
- Merck & Co., Inc.
- AbbVie Inc.
- Melinta Therapeutics LLC
- Paratek Pharmaceuticals, Inc.
- Nabriva Therapeutics plc
- Basilea Pharmaceutica Ltd.
- Johnson & Johnson
- Others
Recent Developments:
- In March 2026, Pfizer Inc. introduced enhanced antibiotic treatment protocols supported by AI-based infection monitoring systems for acute bacterial skin and skin structure infection management across US healthcare facilities.
- In September 2025, Melinta Therapeutics LLC expanded its infectious disease treatment portfolio by launching advanced intravenous antibiotic therapies designed for complicated skin infections and resistant bacterial strain applications.
Market Segmentation:
United States Acute Bacterial Skin and Skin Structure Infection Market, By Drug Class
- Lipoglycopeptide Antibiotics
- Cephalosporins
- Oxazolidinones
- Glycylcyclines
- Others
United States Acute Bacterial Skin and Skin Structure Infection Market, By Application
- Hospital Treatment
- Outpatient Care
- Specialty Clinics
- Others
United States Acute Bacterial Skin and Skin Structure Infection Market, By End User
- Hospitals
- Ambulatory Care Centers
- Specialty Infectious Disease Clinics
- Research Institutions
- Others
Expert Views:
The US acute bacterial skin and skin structure infection market will most likely see steady growth because healthcare providers are progressively asking for more advanced antimicrobial therapies, more precise diagnostics, and faster infection management options to push better patient outcomes and lessen those hospitalization burdens. A lot of analysts mention that lipoglycopeptide antibiotic drugs, along with hospital-based treatment applications, are still going to lead the market, even as things keep moving. At the same time, improvements in long-acting antibiotic formulations, AI-powered infection monitoring, and antimicrobial stewardship tools should make care more efficient and help speed up market growth in the next few years.
Author: Govind and Krishna By Spherical Insights and Consulting